第64回日本神経学会学術大会

第64回日本神経学会学術大会

2023年5月31日〜6月3日幕張メッセ
日本神経学会学術大会
第64回日本神経学会学術大会

第64回日本神経学会学術大会

2023年5月31日〜6月3日幕張メッセ

[HT-05-4]Issues in clinical trials of disease-modifying therapies for Parkinson's disease

Thomas Foltynie1,2(1.UCL Institute of Neurology, 2.National Hospital for Neurology & Neurosurgery)
photo
Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa. He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, and has been UCL’s PI for multi-centre trials of gene therapy and cell therapy as potential neurorestorative approaches for PD. He is the chief investigator for the Edmond J Safra Accelerating Clinical trials in PD project which will establish a platform for the testing of multiple potential neuroprotective approaches simultaneously in the UK.

閲覧にはパスワードが必要です

抄録パスワード認証
パスワードは「第64回日本神経学会学術大会プログラム・抄録集」の18ページに記載してあります。